Elsevier Global Medical News -- Daily treatment with a selective cyclo-oxygenase-2 inhibitor triggered significantly fewer lower gastrointestinal adverse events than did a nonsteroidal anti-inflammatory drug plus a proton pump inhibitor, in a randomized trial with more than 4,000 patients.
